anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a gelatinous antipruritic drug for external use, containing diphenhydramine, an aliphatic higher alcohol and base at a pH value within a specific range, excellent in feeling of use, good in percutaneous absorption and capable of exhibiting excellent antipruritic effects. CONSTITUTION:A drug for external use at a pH value of 10-11, containing diphenhydramine, an aliphatic higher alcohol, preferably lauryl alcohol or oleyl alcohol as a percutaneous absorbefacient and a base, e.g. an aliphatic amine or inorganic base as the percutaneous absorbefacient, having preferably volatility from the skin (e.g. aqueous ammonia) and gelatinized by a gelling agent (preferably carboxyvinyl polymer). The amounts of the ingredients blended in the whole formulation are preferably as follows. 1-15wt.% aliphatic higher alcohol, the base in an amount so as to regulate the pH value to 10-11 and 0.5-2wt.% gelling agent. Water and a lower alcohol are preferably used as a solvent.
At the clinic, participants were administered a single oral dose of 90 mg Dasatinib (Amorphous Solid Dispersion Film-Coated Tablet) on Day 1 after an overnight fast of at least 9 hours. Dasatinib was given with approximately 240 mL of room temperature water. Fasting continued for at least 4 hours following drug administration, after which a standardized lunch was served.
PURPOSE:To obtain an active oxygen remover containing a specific compound such as syringyl glycerol as active ingredient and useful as a cosmetic, a medicine composition and a food composition. CONSTITUTION:This active oxygen remover contains a compound expressed by formula I (R1 and R2 each independently H or a short-chain length alkoxyl) and/or its physiologically permissible salt as an active ingredient. Especially, syringyl glycerol of formula II, guaiabyl glycerol of formula III or 4- hydroxyphenyl-glycerol of formula IV is preferably used as the compound of formula I. Wrinkles and alopecia are prevented and improved and occurrence of unpreferable smell such as body odor can be prevented by using the active oxygen remover as a cosmetic. When the remover is prepared as a medicine, the remover can be formulated in injection, powdery preparation, granule, tablet, capsule, liquid preparation, etc. The remover is effective against inflammation, senile dementia, cardiac infarction, allergic diseases, liver disorders rheumatism, etc. Further, the remover can be used for foods such as candy, silverberry, jelly, juice and bread.
The primary objective of this review was to create a 'trustworthy,' living systematic review and meta-analysis for the application of manual therapy interventions in treating patients with shoulder dysfunction. Included studies were English-language randomized controlled trials published between 1/1/2010 and 8/3/2023, with searches performed in: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), CINHAL, ProQuest Nursing & Allied Health, EBSCO Medline, and PEDro. The population of focus included adults 18 years and older with musculoskeletal impairments related to shoulder dysfunction. Our primary outcomes included pain and region-specific outcome measures. We excluded trials, including participants having shoulder dysfunction resulting from surgery, radicular pain, instability/dislocation, fracture, lymphedema, and radiation. Our screening methodology was based upon a previously published 'trustworthy' systematic review protocol. This included the application of our PICOTS criteria in addition to screening for prospective clinical trial registration and following of prospective intent, as well as assessment of PEDro scores, risk-of-bias ratings, GRADE scoring, and examination of confidence in estimated effects. Twenty-six randomized controlled trials met our PICOTS criteria; however, only 15 of these were registered. Only three were registered prospectively. Two of these did not have discussions and conclusions that aligned with their primary outcome. The remaining single study was found to have a high risk-of-bias, meaning the remainder of the protocol could not be employed and that no randomized controlled trials could undergo further assessment or meta-analysis. The results of this systematic review indicate there are no 'trustworthy' randomized controlled trials examining the effectiveness of manual therapy interventions for the treatment of patients with shoulder dysfunction, as defined by the prospectively established methodology. Therefore, these findings signal that creating a 'trustworthy,' living systematic review on this clinically relevant topic is not yet possible due to a lack of 'trustworthy' randomized controlled trials.
The primary goal of this randomized, controlled trial is to determine if ERT stabilizes, retards, and/or reverses the progression of atherosclerosis in postmenopausal women. We will further evaluate the association of lipid and non-lipid factors of ERT-mediated reduction in the progression of early atherosclerosis. Ultrasonography will be used to measure the rate of change in the thickness of the carotid artery. Blood samples will be used for measuring lipid and non-lipid mediators of ERT.

A total of 222 healthy postmenopausal women 46 to 80 years old without CVD symptoms will be randomized to receive either micronized 17B-estradiol (Estrace) 1mg/day, or a matching placebo tablet daily. All women will be on a low fat/low cholesterol diet, and will receive pravastatin if their LDL cholesterol level exceeds 160 mg/dL. Participants will undergo ultrasonography at baseline and every 6 months throughout the 2 years of randomized treatment. Measurements of lipid and non-lipid biochemical markers will also be done at baseline and every 6 months.
Participants come from two clinics and will be randomly allocated to this group. Participants will go through a transition program which will last for 2 years. The intervention will be performed by specialist nurses.
PURPOSE:The titled removing agent comprising food fibers obtained from beet containing both water-soluble food fibers and insoluble fibers as an active ingredient. CONSTITUTION:An agent for removing mutagenic compound toxicity contained in food and drink in the digestive organs, containing food fibers as an active ingredient obtained from beet pulp (residue after extraction of soluble components such as saccharide, etc. from beet: e.g., table I), containing conjugated fibers of water-soluble food fibers such as pectin, hemicellulose, cellulose, etc. and insoluble fibers. Compressed pulp such as one shown by the table I is optionally ground and used in a powdery state. The agent is orally taken, mutagenic compounds existing in the digestive organs are adsorbed on it, mutagenic compound toxicity is eliminated and excreted out of the body. The amount of intake is sufficiently 3-15g/person/day as the active ingredient (5wt% water content) and the agent is mixed or processed with various foods.
Given the high prevalence of overweight and obesity amongst educators, this study investigated the feasibility of the 16-week Health4LIFE weight loss intervention for primary school educators living with overweight/obesity in low-income settings in Cape Town, South Africa. The research comprised two sub-studies, a pilot randomised controlled trial testing the intervention (10 intervention, n = 79 and 10 control schools, n = 58), and an investigation of the perceptions of participating educators and principals. Feasibility outcomes included reach, applicability, acceptability, implementation integrity, and a hypothesis-generating signal of effect on lifestyle factors and weight. The intervention consisted of a wellness day, weight loss manual, and text messages. Results indicated acceptable reach, with positive feedback on intervention components from principals and educators. Implementation was largely successful, though three schools dropped out due to scheduling issues. Barriers included interruption of teaching time and busy school schedules. The intervention group (n = 42) showed favourable shifts in belief patterns, stages of change, and lifestyle behaviours, with a trend towards weight loss. Control group (n = 43) changes were limited to dietary intake. The triangulation of results supported the intervention's feasibility in terms of primary and secondary outcomes. Recommendations for enhancement include adding in-person follow-up sessions and an app-based element to potentially increase impact on lifestyle indicators and weight loss.
The PROPEL program involves both group aerobic exercise (as described above) and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
Singe dose of orally administered VXA-G1.1-NN (low dose) Oral Vaccine Tablet. VXA-G1.1-NN is an E1/E3-deleted replication-defective Adenovirus serotype 5 vaccine vector for prevention of noroviral gastroenteritis caused by Norovirus GI.1. The vaccine vector encodes for a full length VP1 (major capsid protein) gene from Norvirus GI.1 Norwalk.
Patients receive nivolumab IV over 60 minutes and ipilimumab IV over 90 minutes every 3 weeks for 12 weeks. Patients then receive nivolumab IV over 60 minutes every 2 weeks for 36 weeks in the absence of disease progression or unacceptable toxicity.
Group 6 are participants without metabolic abnormality in the intervention group. Group 6 use the meridian therapy instrument with two weeks. If the suboptimal health status is not improved, then the meridian therapy instrument will continue to be used with an interval of one week.
the study was planned as a student's master thesis. the whole study was carried out by us. all evaluations were completed. all analyses were completed. It is an observational study. It is a survey study.The study data were entered retrospectively.

Research İzmir Bayraklı District Health Directorate No. 1 Healthy Life Centre (1 October 2021 - 15 November 2021) and Gaziemir Municipality (15 November 2021 - 15 March 2022) was conducted. Dokuz Eylül University Ethics Committee accepted the study on 22.12.2021 with the decision number 2021/38-08. People with Body Mass Index ≥ 30 kg/m2 and who met the inclusion/exclusion criteria were included in the study. In addition to the Laval Questionnaire, the SF-12 general health quality of life questionnaire and the Obese-Specific Quality of Life Scale were used. For the adaptation of the Turkish version of the questionnaire, first, language validity was ensured by back translation method.
HF is a major public health problem in the United States, affecting approximately 5 million adults. Despite recent advances in pharmacologic therapy and technologic devices, HF is the most common reason for hospitalization among Medicare patients and is reaching epidemic proportions as the population ages. New and inexpensive interventions that can improve functional capacity and quality of life and can delay disease progression are needed. Tai chi is a popular mind-body exercise that is a potential treatment for heart disease. This exercise incorporates both gentle physical activity and meditation, and it may be particularly suited to frail patients with HF. This study will examine the effects of a tailored tai chi program on functional capacity and quality of life in patients with HF.

Participants will be randomly assigned to either a tai chi program or heart health education for 12 weeks. Participants in both groups will undergo a bicycle stress test at study entry and will receive weekly training sessions of their assigned intervention. Self-report scales and questionnaires will be used to assess participants at study start and at the end of 12 weeks.
Objective: Nonalcoholic fatty liver disease (NAFLD) is more prevalent in patients with obesity, diabetes, and metabolic syndrome, which are risk factors for nonalcoholic steatohepatitis and liver fibrosis. NAFLD is related to cardiovascular outcomes in diabetes. We aimed to investigate the relationship between diabetic complications and NAFLD fibrosis score (NFS) and Fibrosis-4 score (FIB-4). Methods: Three hundred patients with type 2 diabetes mellitus (T2DM) were retrospectively evaluated according to NAFLD diagnosis on ultrasound in outpatient clinic. Risk of advanced fibrosis was estimated using FIB-4 and NFS. Diabetic complications of the patients were noted. Results: Presence of diabetic retinopathy is related to FIB-4 (P = 0.001) and NFS (P < 0.001) scores. NFS score (P = 0.037), not FIB-4 (P = 0.517), is related to diabetic nephropathy. Among macrovascular complications, only coronary artery disease is related to NFS and FIB-4 scores (P = 0.037 and P = 0.004, respectively). Although we cannot establish any association between fasting blood glucose, glycosylated hemoglobin (HbA1c) values and noninvasive liver fibrosis scores (P > 0.05), diabetes duration, and age positively correlated with the FIB-4 score (P = 0.033, P = 0.001). In logistic regression analysis, NFS > 0.676 values are associated with increased rates of diabetic retinopathy, independent of age, sex, HbA1c, and duration diabetes (odds ratio: 1.155, P = 0.030). FIB-4 has no relation with microvascular complications according to logistic regression analysis (P > 0.05 for all). Neither FIB-4 nor NFS has an effect on the presence of macrovascular complications (P > 0.05 for all). Conclusion: Our findings suggest that increase in NFS score is associated with the presence of diabetic retinopathy, independent of confounding factors. Further studies are needed on the applicability of noninvasive fibrosis scores in monitoring the presence of diabetic microvascular and macrovascular complications.
PURPOSE: Transanal minimally invasive surgery (TAMIS) is an advanced transanal platform that can be utilised to perform high-quality local excision (LE) of rectal neoplasia. This study describes clinical and midterm oncological outcomes from a single unit's 7-year experience with TAMIS.
METHODS: Consecutive patients who underwent TAMIS LE at our institution between January 1st, 2016, and December 31st, 2022, were identified from a prospectively maintained database. Indication for TAMIS LE was benign lesions not amenable to endoscopic excision or histologically favourable early rectal cancers. The primary endpoints were resection quality, disease recurrence and peri-operative outcomes. The Kaplan-Meier survival analyses were used to describe disease-free survival (DFS) for patients with rectal adenocarcinoma that did not receive immediate salvage proctectomy.
RESULTS: There were 168 elective TAMIS LE procedures performed for 102 benign and 66 malignant lesions. Overall, a 95.2% negative margin rate was observed, and 96.4% of lesions were submitted without fragmentation. Post-operative morbidity was recorded in 8.3% of patients, with post-operative haemorrhage, being the most common complication encountered. The mean follow-up was 17 months (SD 15). Local recurrence occurred in 1.6%, and distant organ metastasis was noted in 1.6% of patients.
CONCLUSIONS: For carefully selected patients, TAMIS for local excision of early rectal neoplasia is a valid option with low morbidity that maintains the advantages of organ preservation.
The invention relates to the technical field of medicines, in particular to a preparation method and application of 5-dehydroxy-hexahydro demethoxycurcumin extracted from curcuma zedoary, wherein the preparation method comprises the following steps: (1) Pulverizing rhizome of zedoary turmeric, leaching with ethyl acetate, concentrating the leaching solution to obtain residual extract, separating the extract by silica gel column chromatography, and gradient eluting with petroleum ether-ethyl acetate mixed solution to obtain six components Fr.I-VI; (2) Component Fr. III is siliconPerforming gel column chromatographic separation, and performing gradient elution by using petroleum ether-ethyl acetate mixed solution to obtain 5 components Fr. III 1-Fr. III 5; (3) Separating component Fr. III 3 by medium pressure reverse phase silica gel column chromatography with MeOH-H  2  Gradient elution is carried out on the O solution to obtain 9 subfractions Fr. III 3 a-Fr. III 3i; (4) Separating the subfraction Fr. III 3d by a high performance liquid chromatography semi-preparative column to obtain the 5-dehydroxy-hexahydro demethoxycurcumin. The 5-dehydroxy-hexahydro demethoxycurcumin has good anti-inflammatory activity and can be applied to the preparation of anti-inflammatory drugs.
Title compds. are silybin hemi-esters with 1 or 2 mol of succinic acid or with 1 mol of phthalic acid and their salts with pharmacologically tolerable bases. They may be prepd. by reacting silybin with 1-3 equivs. of succinic or phthalic anhydride in the presence of pyridine at between room temp. and 100 degrees C treating the reaction mixture with an acid, and opt. converting the resulting hemi-ester into a salt with a base. Alternative processes for preparing the hemi-succinates are also claimed.
Bronchobiliary fistulas are defined as an abnormal communication between the biliary system and the bronchial tree. They are extremely rare complications of radiofrequency or microwave ablation. A 39-year-old woman with a history of neuroendocrine pancreatic carcinoma suffering from liver metastasis was treated with microwave ablation (MWA). In this case report, we present a case of intractable biliptysis from a bronchobiliary fistula secondary to an MWA. The patient was diagnosed by endoscopic retrograde cholangiopancreatograph and hepatobiliary scintigraphy. Treatment involved a right hemihepatectomy, a redo-hepaticojejunostomy, and the surgical placement of a transhepatic drain. After 6 weeks of drain placement, this could be removed. The fistula was thus successfully treated.
PROBLEM TO BE SOLVED: To produce a food material, capable of suppressing the dark browning, hygroscopicity and decomposition of a contained fructooligosaccharide and manifesting sufficient stability and useful for preventing obesity, diabetes, etc., by using a tuberous root powder prepared by regulating a pressed juice from a tuberous root part of Yacon (botanical name: Polymina sonchifolia) to a specific pH and drying the regulated juice. SOLUTION: This food material is prepared by crushing and homogenizing (A) a tuberous root part of Yacon, providing a pressed juice, then regulating the pH thereof to 6.5-9.5, further drying the regulated juice and using the resultant tuberous root powder. The tuberous root powder is obtained by washing, e.g. the component A with water, removing a pellicle, finely cutting the resultant root to a suitable size, then homogenizing the cut root, adding the prepared pressed juice to an aqueous solution of an alkali, stirring the mixture, regulating the mixture to a prescribed pH, further passing the regulated mixture through a sieve of a suitable mesh (e.g. 200 mesh) and drying the mixture according to a spray-drying method.  The food material is capable of carrying out various green colorings according to the pH of a food to be formulated without causing a change in taste or aroma and useful even in the food field requiring the fashionability.
Cesarean section may result in great trauma and postoperative pain. Besides incision pain, uterine contraction pain is another source of postoperative pain after cesarean section. In clinical practice, a large amount of uterine contraction agent is routinely applied after cesarean section so as to promote involution of uterus and reduce postoperative hemorrhage, which also causes great uterine contraction pain. Acute pain is the risk factor of chronic pain, and may postpone the recovery from labour and influence the quality of life of parturient. Though various analgesia modules have been attempted, more than 20% parturients still experience severe postoperative pain, and pain management after cesarean section remains a challenge to anesthesiologists.

Opiate drugs constitute the baseline medication for postoperative analgesia. However, pure μ opioid receptor agonist like morphine and fentanyl may induce adverse effects such as nausea, vomiting, dizziness, drowsiness and respiratory depression. Nalbuphine hydrochloride is an opiate-like substance structure-related oxymorphone, which is a κ receptor agonist/μ receptor partial antagonistic type analgesia drug. Specific κ receptor agonist and gene knockout experiment reveals that κ receptor agonist depresses the visceral pain induced by chemical stimulation, the effect of which outperforms pure μ opioid receptor agonist. Studies have discovered that some κ receptor agonists can reduce or inhibit the side effects of μ receptor agonist such as tolerance or dependence. The adverse effects of μ receptor agonist such as pruritus, nausea, vomiting, delayed gastric emptying are caused by the drug on peripheral opioid receptor, and can be relieved by opioid receptor agonist. The structure of nalbuphine hydrochloride is related to naloxone, an opioid receptor antagonist, therefore, the incidence of adverse effects of nalbuphine hydrochloride is lower than that of μ receptor agonist. In recent years, nalbuphine hydrochloride has become more and more popular in postoperative analgesia. There has been reports on intrathecal administration of nalbuphine hydrochloride for analgesia after cesarean section, while the effect of intravenous administration of nalbuphine hydrochloride on analgesia after cesarean section remains undetermined. This study aim to compare the effects of nalbuphine hydrochloride vs sufentanil citrate on patient-controlled intravenous analgesia after cesarean section.
Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Subject's usual fast-acting insulin analog will be infused using a subcutaneous infusion pumps (Accu-Chek Combo, Roche). The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer every 10 minutes. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
An RCT will be conducted on female patients with radiculopathy due to posterolateral disc herniation at L4-S1 levels, visiting Physiotherapy OPD at DUHS Ojha campus. A sample of 70 patients was calculated using PASS v11 software (Microsoft, Redmond, WA, USA). For estimating sample size, pain scores of motor control group (3.4 ±0.9) and motor control+ NDS group (2.5 ±0.8) after 8th session was used from a study conducted earlier. Patients who fulfill the inclusion criteria will be included in the study through convenience sampling, and will be equally allocated either in Core stabilization exercises group A (Control group: n=35) or Core stabilization exercises with Neural mobilization technique group B (Experimental group: n=35). Treatment will be provided on alternate days 3 times a week for 4 consecutive weeks. Patients will be assessed for pain and functional disability prior to the treatment, then at the end of 2nd week and 4th week through 11 points NPRS and Modified Oswestry Disability Questionnaire (MODQ). Data will be entered and analyzed through IBM SPSS version 24 with p-value \< 0.05 will be considered as statistically significant.